• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Choosing Wisely: Insights from an MAIC and eXalt3

Opinion
Video

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).

Related Videos
Jorge J. Nieva, MD, Keck School of Medicine
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
5 experts are featured in this series
4 experts in this video
© 2025 MJH Life Sciences
AJMC®
All rights reserved.